Addiction to transmucosal fentanyl: Is it a cause for concern in cancer pain management?

Abstract

Get full access to this article

View all access options for this article.

References

Twycross

Prommer

Mihalyo

. Fentanyl (transmucosal). J Pain Symptom Manage 2012; 44(1): 131–149.

Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS), http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM289730.pdf

Passik

Kirsh

. Weighing in on the off-label use of Actiq for noncancer-related pain: a recipe for success or a recipe for disaster? Pain Med 2007; 8(2): 130–133.

Nunez-Olarte

Alvarez-Jimenez

. Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain. J Pain Symptom Manage 2011; 42(6): e6–e8.

Passik

Messina

Golsorkhi

. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manage 2011; 41(1): 116–125.